DB17819ExperimentalNucleic Acid Based Therapies
Apc001 is an aptamer developed for the treatment of osteogenesis imperfecta.
- Mechanism
- Curator reviewed
Pharmacologically active on Sclerostin
- Code names
- Apc001
Resolves to
Targets
What you can answer from here — as of July 08, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Apc001, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account